JP2000517299A5 - - Google Patents

Download PDF

Info

Publication number
JP2000517299A5
JP2000517299A5 JP1998508981A JP50898198A JP2000517299A5 JP 2000517299 A5 JP2000517299 A5 JP 2000517299A5 JP 1998508981 A JP1998508981 A JP 1998508981A JP 50898198 A JP50898198 A JP 50898198A JP 2000517299 A5 JP2000517299 A5 JP 2000517299A5
Authority
JP
Japan
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP1998508981A
Other languages
English (en)
Japanese (ja)
Other versions
JP2000517299A (ja
Filing date
Publication date
Priority claimed from US08/688,613 external-priority patent/US5958892A/en
Application filed filed Critical
Publication of JP2000517299A publication Critical patent/JP2000517299A/ja
Publication of JP2000517299A5 publication Critical patent/JP2000517299A5/ja
Ceased legal-status Critical Current

Links

JP10508981A 1996-07-30 1997-07-24 癌細胞における２―メトキシエストラジオール誘導アポトーシス Ceased JP2000517299A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/688,613 1996-07-30
US08/688,613 US5958892A (en) 1996-07-30 1996-07-30 2-methoxyestradiol-induced apoptosis in cancer cells
PCT/US1997/012998 WO1998004291A1 (en) 1996-07-30 1997-07-24 2-methoxyestradiol-induced apoptosis in cancer cells

Publications (2)

Publication Number Publication Date
JP2000517299A JP2000517299A (ja) 2000-12-26
JP2000517299A5 true JP2000517299A5 (Direct) 2005-04-07

Family

ID=24765087

Family Applications (1)

Application Number Title Priority Date Filing Date
JP10508981A Ceased JP2000517299A (ja) 1996-07-30 1997-07-24 癌細胞における２―メトキシエストラジオール誘導アポトーシス

Country Status (8)

Country Link
US (3) US5958892A (Direct)
EP (1) EP0921821B1 (Direct)
JP (1) JP2000517299A (Direct)
AT (1) ATE279212T1 (Direct)
AU (1) AU723401B2 (Direct)
CA (1) CA2262533A1 (Direct)
DE (1) DE69731213T2 (Direct)
WO (1) WO1998004291A1 (Direct)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5504074A (en) * 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US20030064949A1 (en) * 1998-02-17 2003-04-03 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
US20030060434A1 (en) * 1997-02-18 2003-03-27 Loretta Nielsen Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms
BR9915940A (pt) * 1998-12-02 2001-09-11 Pfizer Prod Inc Métodos e composições para restaurar a estabilidade conformacional de uma proteìna da famìlia p53
US6548541B1 (en) * 1999-04-21 2003-04-15 Unitech Pharmaceuticals, Inc. Carboplatin analogs for cancer treatment
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
AU5010500A (en) * 1999-05-12 2000-11-21 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6518261B2 (en) * 2000-03-17 2003-02-11 Oncology Sciences Corporation Use of eugenol in combination with other chemopreventative agents as prophylaxis for cancers
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) * 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
US20050192258A1 (en) * 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
AU2002232407A1 (en) 2000-10-30 2002-05-15 Board Of Regents, The University Of Texas System Methods, compositions and therapeutic applications relating to fortilin (= translationally controlled tumor protein, tctp) and modulators thereof
WO2002062348A1 (en) * 2001-02-05 2002-08-15 Oncology Sciences Corporation Eugenol, optionally in combination with 2-methoxyestradiol, as a cancer chemopreventative agent
WO2002079167A1 (en) * 2001-03-30 2002-10-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Geldanamycin derivative and method of treating cancer using same
US20030187076A1 (en) * 2002-01-30 2003-10-02 Agoston Gregory E. Non-steroidal analogs of 2-methoxyestradiol
WO2003073985A2 (en) * 2002-03-01 2003-09-12 Entremed, Inc. New methods of using antiangiogenic agents
WO2003080027A1 (en) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Nanoparticulate compositions of angiogenesis inhibitors
MXPA05000778A (es) 2002-07-18 2005-08-29 Helix Biopharma Corp Uso de ureasa para inhibir el crecimiento de celulas cancerosas.
EP2298315A1 (en) 2002-08-28 2011-03-23 Harbor BioSciences, Inc. Therapeutic treatment methods
AU2004204778B2 (en) * 2003-01-10 2008-05-22 Threshold Pharmaceuticals, Inc. Treatment of cancer with 2-deoxyglucose
US7160908B2 (en) * 2003-03-04 2007-01-09 Unitech Pharmaceuticals, Inc. Dynamic anticancer platinum compounds
EP1633367A2 (en) * 2003-05-28 2006-03-15 EntreMed, Inc. Antiangiogenic agents
US7498322B2 (en) * 2004-03-12 2009-03-03 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
AU2005284714A1 (en) * 2004-09-13 2006-03-23 Pr Pharmaceuticals, Inc. Long acting injectable crystal formulations of estradiol metabolites and methods of using same
EP1819343A2 (en) * 2004-11-29 2007-08-22 EntreMed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
US20070185069A1 (en) * 2005-11-14 2007-08-09 Plum Stacy M Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
US20070176403A1 (en) * 2006-02-01 2007-08-02 Dennis Calderone Air adjustable seat
US8658633B2 (en) * 2006-02-16 2014-02-25 Massachusetts Eye And Ear Infirmary Methods and compositions for treating conditions of the eye
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
US9029322B2 (en) 2007-06-05 2015-05-12 Cornell University Compounds for enhancing p21 expression and methods of use thereof
KR20090009637A (ko) * 2007-07-20 2009-01-23 삼성전자주식회사 엠비-오에프디엠 시스템 및 프레임 바운더리 검출 방법
CA3001054C (en) * 2015-10-08 2021-12-14 University Of Utah Research Foundation Elephant p53 proteins and nuleic acids encoding the same for preventing or treating cancer
KR101837735B1 (ko) * 2016-08-08 2018-04-19 성균관대학교산학협력단 TCTP (Translationally controlled tumour protein) 단백질을 포함하는 난모세포(oocytes) 노화 방지 또는 수정능력 개선용 조성물

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532220A (en) 1987-08-31 1996-07-02 The Regents Of The University Of California Genetic mechanisms of tumor suppression
ATE161039T1 (de) 1988-10-31 1997-12-15 Univ California Erzeugnisse und verfahren zur regelung der suppression von neoplastischen phenotypen
EP0390323B2 (en) 1989-03-29 2012-08-08 Johns Hopkins University Detection of loss of the wild-type p53 gene
US5527676A (en) 1989-03-29 1996-06-18 The Johns Hopkins University Detection of loss of the wild-type P53 gene and kits therefor
IE911115A1 (en) 1990-04-10 1991-10-23 Canji Inc Gene therapy for cell proliferative diseases
US6410010B1 (en) * 1992-10-13 2002-06-25 Board Of Regents, The University Of Texas System Recombinant P53 adenovirus compositions
US5747469A (en) * 1991-03-06 1998-05-05 Board Of Regents, The University Of Texas System Methods and compositions comprising DNA damaging agents and p53
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
DK0689447T3 (da) 1993-02-16 1999-10-18 Onyx Pharma Inc Cytopatiske vira til behandling af og profylakse for neoplasia
FR2704234B1 (fr) 1993-04-22 1995-07-21 Centre Nat Rech Scient Virus recombinants, preparation et utilisation en therapie genique.
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
KR100356615B1 (ko) 1993-07-13 2003-04-03 아방티 파르마 소시에테 아노님 결함아데노바이러스벡터및유전자치료에서그의사용
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
FR2712602B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
FR2716893B1 (fr) 1994-03-03 1996-04-12 Rhone Poulenc Rorer Sa Virus recombinants, leur préparation et leur utilisation thérapeutique.

Similar Documents

Publication Publication Date Title
JP2000517304A5 (Direct)
JP2000516561A5 (Direct)
JP2000501018A5 (Direct)
JP2000500076A5 (Direct)
JP2001503008A5 (Direct)
JP2000513357A5 (Direct)
JP2000501324A5 (Direct)
JP2000500055A5 (Direct)
JP2000500026A5 (Direct)
JP2000502472A5 (Direct)
JP2000504267A5 (Direct)
JP2000501338A5 (Direct)
JP2000500874A5 (Direct)
JP2000502485A5 (Direct)
JP2000502425A5 (Direct)
JP2000502568A5 (Direct)
JP2000500912A5 (Direct)
JP2000502570A5 (Direct)
JP2000517299A5 (Direct)
JP2000512095A5 (Direct)
JP2000513111A5 (Direct)
JP2000501229A5 (Direct)
JP2000500857A5 (Direct)
JP2000502316A5 (Direct)
JP2000502714A5 (Direct)